Nivolumab And Immune-Mediated Colitis
CLINICAL CASE REPORTS(2019)
摘要
Key Clinical Message Nivolumab is associated with a number of immune-regulated adverse events, including immune-mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms compared to previous reported cases, using higher dosing, thereby minimizing hospitalization.
更多查看译文
关键词
immune-mediated colitis, immune-regulated adverse events, Nivolumab, PD-1 receptor
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要